Following a successful global search by The RSA Group, Daiichi Sankyo Europe GmbH is pleased to announce the appointment of Dr Giacomo Mordenti as Executive Director, Head of Biostatistics & Data Management Europe. Daiichi Sankyo is a global pharmaceutical company primarily focused on the development of novel therapies in oncology, rare diseases and immune disorders.
Giacomo brings over 20 years of experience from the pharmaceutical and medical device sectors, having led several departments in biostatistics, data management and data analytics across multiple therapeutic areas. Most recently, he was the Senior Director and Global Head of Statistics & Data Management at LivaNova. Previous to this Giacomo was the Senior Director and Head of Biostatistics at the Grünenthal Group and has also held senior roles at Merck Serono and Menarini Ricerche S.p.A.
During this unprecedented period of uncertainty, Giacomo’s appointment demonstrates that for life science companies, business can and will continue. This is highlighted by the fact that the RSA Group were able to successfully complete this search despite Giacomo being based in Italy and unable to travel. Modern technology has made remote communication stronger and easier than ever, be that for a client to convey a brief, the sourcing of suitable candidates or during the interview process.
Dr Andy Theodorou, Senior Consultant and Kristian Juergensen Chief Commercial Officer commented, “Undeterred by the global pandemic, Giacomo’s appointment followed an extensive global search and careful candidate due diligence by our team. This excellent outcome demonstrates the RSA Group’s ability to engage the best candidates in their fields, despite restrictions on international travel and global economic uncertainty.”
Heike van Kampen, Sr. HR Business Partner Europe at Daiichi Sankyo Europe GmbH, added, “Biostatistics and data management are very important in helping us to achieve our goals and complete projects. Our goals and vision remain the same despite the coronavirus pandemic and the fight against cancer cannot stop even in the face of such adversity. We are therefore delighted to have been able to attract a candidate with Giacomo’s expertise and experience to join Dr Zhenming Shun’s VP Statistics and Data Management team even during this challenging period. We are grateful to the RSA Group for their excellent advice throughout the process.”